Dr. Trevor Pugh

As Director of the Joint Genomics Program of the University Health Network and Ontario Institute for Cancer Research (OICR), Dr. Pugh investigates the clinical implications of clonal shifts in cancer and non-cancerous cell populations during treatment. He is a board-certified molecular geneticist (ABMG/ACMG) and cancer genomics researcher specializing in application of cell-free DNA, immune repertoire, and single cell RNA-seq sequencing to clinical specimens. Dr. Pugh has been recognized by Canada’s Top 40 Under 40, Canadian Cancer Society Bernard and Francine Dorval Prize, the Web of Science Highly Cited Researchers List (top 1% of citations by field internationally in 2019 and 2020), a Terry Fox New Investigator Award, the Till and McCulloch Paper of the Year award, and the Canada Research Chair in Translational Genomics. His major research contributions include the establishment of ctDNA changes as a predictor of immunotherapy response; invention of a hybrid-capture method for immune repertoire profiling; pioneering ctDNA sequencing and establishing clinical laboratory guidelines for multiple myeloma; genome characterization of several pediatric solid tumours; and deployment of genome technologies and software to support clinical genomic testing.